NO20081465L - Anti-IL-23 antistoffer - Google Patents

Anti-IL-23 antistoffer

Info

Publication number
NO20081465L
NO20081465L NO20081465A NO20081465A NO20081465L NO 20081465 L NO20081465 L NO 20081465L NO 20081465 A NO20081465 A NO 20081465A NO 20081465 A NO20081465 A NO 20081465A NO 20081465 L NO20081465 L NO 20081465L
Authority
NO
Norway
Prior art keywords
antibodies
antigen
binding portions
subunit
treatment
Prior art date
Application number
NO20081465A
Other languages
English (en)
Norwegian (no)
Inventor
David Matthew Marquis
Kristine Kay Kikly
Craig Duane Dickinson
Alain Philippe Vasserot
Catherine Brautigam Beidler
Stuart Willis Bright
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20081465L publication Critical patent/NO20081465L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
NO20081465A 2005-08-25 2008-03-25 Anti-IL-23 antistoffer NO20081465L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71133605P 2005-08-25 2005-08-25
US77235506P 2006-02-10 2006-02-10
PCT/US2006/032752 WO2007024846A2 (en) 2005-08-25 2006-08-23 Anit-il-23 antibiodies

Publications (1)

Publication Number Publication Date
NO20081465L true NO20081465L (no) 2008-05-15

Family

ID=37616511

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081465A NO20081465L (no) 2005-08-25 2008-03-25 Anti-IL-23 antistoffer

Country Status (21)

Country Link
US (1) US7872102B2 (de)
EP (1) EP1937721B1 (de)
JP (1) JP5022367B2 (de)
KR (1) KR101028200B1 (de)
AT (1) ATE475672T1 (de)
AU (1) AU2006283194B9 (de)
BR (1) BRPI0615018A2 (de)
CA (1) CA2619052A1 (de)
CY (1) CY1110792T1 (de)
DE (1) DE602006015830D1 (de)
DK (1) DK1937721T3 (de)
EA (1) EA013506B1 (de)
ES (1) ES2347690T3 (de)
HK (1) HK1119712A1 (de)
IL (1) IL188312A0 (de)
MX (1) MX2008002179A (de)
NO (1) NO20081465L (de)
PL (1) PL1937721T3 (de)
PT (1) PT1937721E (de)
SI (1) SI1937721T1 (de)
WO (1) WO2007024846A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005955A2 (en) 2005-06-30 2007-01-11 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
EP3190125A1 (de) * 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Mittels engineering hergestellte anti-il-23r-antikörper
CN102887954B (zh) 2005-12-29 2015-02-04 詹森生物科技公司 人抗il-23抗体、组合物、方法和用途
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
EP2426144B1 (de) 2007-02-23 2018-10-31 Merck Sharp & Dohme Corp. Gentechnisch hergestellte anti-il-23p19-antikörper
WO2008106131A2 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
EP2572729A3 (de) * 2007-08-10 2013-06-05 Regeneron Pharmaceuticals, Inc. Hochaffine humane Antikörper gegen den humanen Nervenwachstumsfaktor
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
AU2008328779B2 (en) 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
MX2011002159A (es) 2008-08-27 2011-03-29 Schering Corp Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria.
SG171724A1 (en) * 2008-11-12 2011-07-28 Schering Corp ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
SG172275A1 (en) 2008-12-19 2011-07-28 Schering Corp Feed supplement for mammalian cell culture and methods of use
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
US20120264917A1 (en) * 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
WO2011011797A2 (en) * 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
WO2011017294A1 (en) 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
ES2776980T3 (es) 2009-12-23 2020-08-03 Merck Sharp & Dohme Línea celular 3M
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
LT2635601T (lt) 2010-11-04 2016-10-10 Boehringer Ingelheim International Gmbh Antikūnai prieš il-23
EP2583979B1 (de) 2011-10-19 2015-12-16 Effimune Verfahren zur Vorbereitung von menschlichem IL-23 gerichtete Antikörper, gegen die p19
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
AR091116A1 (es) 2012-05-22 2015-01-14 Bristol Myers Squibb Co Anticuerpos biespecificos y sus metodos de uso
EP2866833B1 (de) 2012-06-27 2019-05-15 Merck Sharp & Dohme Corp. Kristalline antikörper gegen menschliches il-23
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
EA201591579A1 (ru) 2013-03-15 2016-01-29 Амген Инк. Способы лечения болезни крона при помощи анти-il-23 антитела
EA201591581A1 (ru) 2013-03-15 2016-01-29 Амген Инк. Способы лечения псориаза при помощи анти-il-23 антитела
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
EP3253794A1 (de) 2015-02-04 2017-12-13 Boehringer Ingelheim International GmbH Verfahren zur behandlung von entzündlichen krankheiten
WO2016168282A1 (en) 2015-04-14 2016-10-20 Boehringer Ingelheim International Gmbh Methods of treating diseases
EP3349854A4 (de) 2015-09-17 2019-04-03 Amgen Inc. Vorhersage der klinischen reaktion auf il23-antagonisten mit il23-pfadbiomarkern
TWI733695B (zh) 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
US11220541B2 (en) 2015-12-22 2022-01-11 Amgen Inc. CCL20 as a predictor of clinical response to IL23-antagonists
EP3560956A3 (de) 2016-04-15 2020-01-01 Boehringer Ingelheim International GmbH Verfahren zur behandlung von entzündlichen krankheiten
JP2019536756A (ja) 2016-10-14 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ抗体を用いて疾患を処置する方法
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AR112341A1 (es) 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
AU2019300491A1 (en) 2018-07-13 2021-03-04 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
WO2020104943A2 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
JP2022534020A (ja) 2019-05-23 2022-07-27 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
CN112807428A (zh) * 2020-06-12 2021-05-18 江苏荃信生物医药有限公司 包含抗人白介素23单克隆抗体的药物组合物
CN113156134B (zh) * 2020-11-26 2024-01-23 江苏荃信生物医药股份有限公司 用于检测人白介素23的elisa试剂盒及检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3045480B2 (ja) * 1996-12-20 2000-05-29 大同メタル工業株式会社 ボーリング盤
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
EP1072610B1 (de) * 1998-04-14 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Neues cytokinartiges protein
KR100894359B1 (ko) 1999-09-09 2009-04-22 쉐링 코포레이션 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
BRPI0408247A (pt) * 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
ATE533502T1 (de) * 2004-02-17 2011-12-15 Schering Corp Verfahren zur modulation der il-23-aktivität; relevante reagenzien
CN102887954B (zh) * 2005-12-29 2015-02-04 詹森生物科技公司 人抗il-23抗体、组合物、方法和用途
WO2008103958A1 (en) * 2007-02-22 2008-08-28 Hill's Pet Nutrition, Inc. Compositions and methods for altering gene expression

Also Published As

Publication number Publication date
KR101028200B1 (ko) 2011-04-11
EA200800417A1 (ru) 2008-06-30
US7872102B2 (en) 2011-01-18
ES2347690T3 (es) 2010-11-03
US20090240036A1 (en) 2009-09-24
AU2006283194B9 (en) 2011-02-03
ATE475672T1 (de) 2010-08-15
WO2007024846A3 (en) 2007-06-07
AU2006283194B8 (en) 2010-10-28
JP5022367B2 (ja) 2012-09-12
MX2008002179A (es) 2008-04-22
PT1937721E (pt) 2010-09-17
EP1937721A2 (de) 2008-07-02
AU2006283194A1 (en) 2007-03-01
DK1937721T3 (da) 2010-10-18
CA2619052A1 (en) 2007-03-01
PL1937721T3 (pl) 2010-12-31
CY1110792T1 (el) 2015-06-10
IL188312A0 (en) 2008-04-13
EP1937721B1 (de) 2010-07-28
WO2007024846A2 (en) 2007-03-01
EA013506B1 (ru) 2010-06-30
BRPI0615018A2 (pt) 2011-04-26
DE602006015830D1 (de) 2010-09-09
JP2009506041A (ja) 2009-02-12
KR20080031450A (ko) 2008-04-08
SI1937721T1 (sl) 2010-11-30
HK1119712A1 (en) 2009-03-13
AU2006283194B2 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
ATE475672T1 (de) Anti-il-23-antikörper
CY1121208T1 (el) Σκευασματα αντισωματος ναταλιζουμαμπης
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
EA200870050A1 (ru) Анти-il-17-антитела
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
MX2009006891A (es) Anticuerpos cd44.
WO2014114651A9 (en) Tnf-alpha antigen-binding proteins
NO20084878L (no) Humanisert C-kit antistoff
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
UA92505C2 (ru) Композиции на основе антитела против cd3
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
DK1951759T3 (da) Anti-EGFR-antistoffer
TW200740844A (en) Novel MAdCAM antibodies
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
EA201490677A1 (ru) Связывающие антиген cd27l белки
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
EA200700225A1 (ru) Аналоги тетрапептида
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
EA201390467A1 (ru) Композиции антител и способы применения
EA200800601A1 (ru) Связывающие fas антитела

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application